CTT Pharmaceuticals, Inc. acquired Mindesta Inc. (OTCPK:MDST) in a reverse merger transaction on September 9, 2014. Under the terms of the transaction, Mindesta will issue approximately 149.18 million common shares to the CTT Shareholders. The former shareholders of CTT will own a majority of the outstanding shares of Mindesta's common stock immediately following the execution of the transaction. CTT is deemed to be the accounting acquirer in the transaction. Gregory Bowes resigned after the deal. Mindesta will change its name to CTT Pharmaceuticals, Inc. The transaction is subject to third-party consents, permits, authorizations and approvals of any public, regulatory or governmental body.

CTT Pharmaceuticals, Inc. completed the acquisition of Mindesta Inc. (OTCPK:MDST) in a reverse merger transaction on September 9, 2014.